Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.67 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.67 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.67 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.67 |
| ▸ | IL1RN | P18510 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577215 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL29578349 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL29578343 | 1.00 | OPRM1 (0.67) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL29577668 | 0.99 | ERAP1 (0.68) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL30010303 | 0.99 | ERAP1 (0.68) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL29577129 | 0.99 | ERAP1 (0.68) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL29577265 | 0.97 | ERAP1 (0.66) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL30011658 | 0.97 | ERAP1 (0.66) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL30010730 | 0.97 | ERAP1 (0.66) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL29577019 | 0.97 | OPRM1 (0.67) | OPRM1OPRD1ERAP1ERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| EP-3206704-B1 | PEPTIDES HAVING ANTI-INFLAMMATORY PROPERTIES | RIPTIDE BIOSCIENCE INC (US) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | GPR39, FABP2, GPR119 | OPRM1 2474/4885OPRD1 1276/4885ERAP1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.